Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Moll

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
Environmental Science & Technology|December 28, 2012
Price corrected domestic technology assumption--a method to assess pollution embodied in trade using primary official statistics only. With a case on CO2 emissions embodied in imports to EuropeArnold Tukker, Arjan de Koning, Richard Wood, et al.
Journal of Thrombosis and Thrombolysis|March 23, 2013
Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhageJennifer L Aron, Robert Gosselin, Stephan Moll, et al.
Journal of Thrombosis and Haemostasis : JTH|January 25, 2023
"Hereditary angioedema is associated with an increased risk of venous thromboembolism": replySteven P Grover, Linda Sundler Björkman, Arne Egesten, et al.
American Journal of Hematology|March 22, 2006
False-negative factor V Leiden genetic testing in a patient with recurrent deep venous thrombosisEdward N Libby, Jessica K Booker, Margaret L Gulley, et al.
British Journal of Haematology|December 19, 2013
Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpuraMarshall A Mazepa, Jay S Raval, Stephan Moll, et al.
Leukemia & Lymphoma|March 26, 2014
Epstein-Barr virus reactivation and hemophagocytic lymphohistiocytosis in a patient with chronic lymphocytic leukemiaMing Y Lim, Yuri Fedoriw, Hansa Ramanayake, et al.
Research and Practice in Thrombosis and Haemostasis|July 7, 2023
Advanced practice provider-led clinic for care transitions in newly diagnosed venous thromboembolism: establishment and utilizationCassiopeia Frank, Raj Kasthuri, Nigel S Key, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devicesStephan Moll, Peter Kenyon, Luigi Bertoli, et al.
The American Journal of Medicine|December 22, 2019
Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized PatientsS Walker Mason, Alexandra Barber, Emily Jones, et al.
International Journal of Spine Surgery|September 28, 2020
An Evidence-Based Algorithm for Determining Venous Thromboembolism Prophylaxis After Degenerative Spinal SurgeryJoshua A Shapiro, Matthew R Stillwagon, Alexander G Padovano, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
Environmental Science & Technology|December 28, 2012
Price corrected domestic technology assumption--a method to assess pollution embodied in trade using primary official statistics only. With a case on CO2 emissions embodied in imports to EuropeArnold Tukker, Arjan de Koning, Richard Wood, et al.
Journal of Thrombosis and Thrombolysis|March 23, 2013
Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhageJennifer L Aron, Robert Gosselin, Stephan Moll, et al.
Journal of Thrombosis and Haemostasis : JTH|January 25, 2023
"Hereditary angioedema is associated with an increased risk of venous thromboembolism": replySteven P Grover, Linda Sundler Björkman, Arne Egesten, et al.
American Journal of Hematology|March 22, 2006
False-negative factor V Leiden genetic testing in a patient with recurrent deep venous thrombosisEdward N Libby, Jessica K Booker, Margaret L Gulley, et al.
British Journal of Haematology|December 19, 2013
Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpuraMarshall A Mazepa, Jay S Raval, Stephan Moll, et al.
Leukemia & Lymphoma|March 26, 2014
Epstein-Barr virus reactivation and hemophagocytic lymphohistiocytosis in a patient with chronic lymphocytic leukemiaMing Y Lim, Yuri Fedoriw, Hansa Ramanayake, et al.
Research and Practice in Thrombosis and Haemostasis|July 7, 2023
Advanced practice provider-led clinic for care transitions in newly diagnosed venous thromboembolism: establishment and utilizationCassiopeia Frank, Raj Kasthuri, Nigel S Key, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devicesStephan Moll, Peter Kenyon, Luigi Bertoli, et al.
The American Journal of Medicine|December 22, 2019
Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized PatientsS Walker Mason, Alexandra Barber, Emily Jones, et al.
International Journal of Spine Surgery|September 28, 2020
An Evidence-Based Algorithm for Determining Venous Thromboembolism Prophylaxis After Degenerative Spinal SurgeryJoshua A Shapiro, Matthew R Stillwagon, Alexander G Padovano, et al.
Pageof 13